Cook ELUTES Study Delivers 3% Restenosis Rate In High-Dose Arm

A 3.1% binary in-stent restenosis rate in the highest-dose arm of Cook, Inc.'s European ELUTES trial for the paclitaxel-coated V-Flex Plus coronary stent bodes well for the DELIVER trial in the U.S., to be conducted jointly with Guidant